1346 GMT - The receipt of all regulatory approvals allowing Novo Nordisk's Catalent acquisition is important and should see share price upside as it improves supply visibility, Bank of America Securities analysts Sachin Jain and Graham Parry write. The acquisition is expected to gradually increase Novo's filling capacity from 2026 onwards. However, share price upside potential may be capped given investor nerves into the imminent phase 3 trial data from obesity drug CagriSema, they say. The bank expects around 10% share price upside potential if CagriSema confirms 25% weight loss, versus 15%-20% share price upside potential if weight-loss is over 27%. Shares rise 1.8% to 767.50 Danish kroner. (dominic.chopping@wsj.com)
(END) Dow Jones Newswires
December 16, 2024 08:46 ET (13:46 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。